TY - JOUR
T1 - Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program
AU - Annett, Robert D.
AU - Aylward, Elizabeth H.
AU - Lapidus, Jodi
AU - Bender, Bruce G.
AU - DuHamel, Thomas
N1 - Funding Information:
Supported by contracts from the Department of Health and Human Services, National Heart, Lung, and Blood Institute (NHLBI-HR-90-13).
Funding Information:
Source of funding: The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M010R00051, MO1RR0099720, MO1RR02719-14, and RR00036 from the National Center for Research Resources. The Harvard Community Health Plan Foundation provides additional support for the CAMP center at Brigham and Women’s Hospital.
PY - 2000
Y1 - 2000
N2 - Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.
AB - Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler. All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV1PC20,ΔFEV1 percent predicted, change in peak flow, percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP. Mean performance on neurocognitive variables was found to be similar to that of national normative data.
KW - Asthma severity
KW - Childhood Asthma Management Program
KW - Neurocognitive functioning
UR - http://www.scopus.com/inward/record.url?scp=0034102279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034102279&partnerID=8YFLogxK
U2 - 10.1067/mai.2000.105226
DO - 10.1067/mai.2000.105226
M3 - Article
C2 - 10756221
AN - SCOPUS:0034102279
SN - 0091-6749
VL - 105
SP - 717
EP - 724
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 4
ER -